Calogera Butera, Bruno Colombo, Francesca Bianchi, Marco Cursi, Roberta Messina, Stefano Amadio, Roberta Guerriero, Giancarlo Comi, Ubaldo Del Carro
Onabotulinum toxin A (BT-A) is now one of the authorized prophylaxis treatments for chronic migraine (CM) thanks to previous clinical trials, which usually required a pharmacologic washout as a precondition for demonstrating its efficacy. Aim of our study was to assess the efficacy in daily clinical practice of BT-A injections in refractory CM patients, regardless of medication overuse without any standardized withdrawal protocol and without stopping the ongoing prophylaxis treatment as well. We treated 44 refractory CM patients (37 females and 7 males) trimonthly without any modification in symptomatic, or prophylactic drug therapy...
October 2016: Neurological Sciences